

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 9.270

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2015 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission. ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Editorial

- 951** Conventional DMARDs in axial spondyloarthritis: wishful—rather than rational thinking!
R B M Landewé

Recommendations

- 954** EULAR recommendations for patient education for people with inflammatory arthritis
H A Zangi, M Ndosi, J Adams, L Andersen, C Bode, C Boström, Y van Eijck-Hustings, L Gossec, J Korandová, G Mendes, K Niedermann, J Primdahl, M Stoffer, M Voshaar, A van Tubergen

- 963** Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
M H Buch, L Silva-Fernandez, L Carmona, D Aleitah, R Christensen, B Combe, P Emery, G Ferraccioli, F Guillemain, T K Kvien, R Landewe, K Pavelka, K Saag, J S Smolen, D Symmons, D van der Heijde, J Welling, G Wells, R Westhovens, A Zink, M Boers

Clinical and epidemiological research

- 970** The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study
E Lie, L E Kristensen, H Forsblad-d'Elia, T Zverková-Sandström, J Asklund, L T Jacobsson, for the ARTIS Study Group

- 979** Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
P Emery, J E Gottenberg, A Rubbert-Roth, P Sarzi-Puttini, D Choquette, V M M Taboada, L Barile-Fabris, R J Moots, A Ostor, A Andrianakos, E Gemmen, C Mpofu, C Chung, L H Gylvin, A Finckh

- 985** Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis?
U Weber, V Zubler, Z Zhao, R GW Lambert, S M Chan, S J Pedersen, M Østergaard, K Rüfäbach, W P Maksymowych

- 993** Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden
A J Mohammad, J-Å Nilsson, L TH Jacobsson, P A Merkel, C Turesson

- 998** The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients
E E A Arts, J Fransen, A A den Broeder, C D Popa, P L C M van Riel

- 1004** The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'
L H D van Tuyl, S Hewlett, M Sadlonova, B Davis, C Flurey, W Hoogland, J Kirwan, T Sanderson, D van Schaardenburg, M Scholte-Voshaar, J Smolen, T Stamm, M Boers

- 1011** Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
R Cervera, R Serrano, G J Pons-Estel, L Ceberio-Hualde, Y Shoenfeld, E de Ramón, V Buonaiuto, S Jacobsen, M M Zeher, T Tarr, A Tincani, M Taglietti, G Theodossiadis, E Nomikou, M Galeazzi, F Bellisai, P L Meroni, R H W M Derksen, P G D de Groot, M Baleva, M Mosca, S Bombardieri, F Houssiau, J-C Gris, I Quéré, E Hachulla, C Vasconcelos, A Fernández-Nebro, M Haro, Z Amoura, M Miyara, M Tektonidou, G Espinosa, M L Bertolaccini, M A Khamashia, on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies)

- 1019** The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort
M F Ugarte-Gil, E Acevedo-Vásquez, G S Alarcón, C A Pastor-Asurza, J L Alfaro-Lozano, J M Cucho-Venegas, M I Segami, D Wojdyla, E R Soriano, C Drenkard, J C Brenol, A C de Oliveira e Silva Montandon, L T L Costallat, L Massardo, J F Molina-Restrepo, M Guibert-Toledano, L H Silveira, M C Amigo, L A Barile-Fabris, R Chacón-Díaz, M H Esteva-Spinetti, G J Pons-Estel, G McGwin Jr, B A Pons-Estel, on behalf of GLADEL

- 1024** Weight change and change in tibial cartilage volume and symptoms in obese adults
A J Teichtahl, A E Wluka, S K Tanamas, Y Wang, B J Strauss, J Proietto, J B Dixon, G Jones, A Forbes, F M Cicuttini

- 1030** Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study
N Dalbeth, O Aati, R Kalluru, G D Gamble, A Home, A J Doyle, F M McQueen

- 1037** Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
G-R Burmester, A J Kivitz, H Kupper, U Arulmani, S Florentinus, S L Goss, S S Rathmann, R M Fleischmann

- 1045** Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis
M Haroon, P Gallagher, O FitzGerald

MORE CONTENTS ►

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>



COMMITTEE ON PUBLICATION ETHICS



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics



<http://publicationethics.org/>



equator network



recycle
When you have finished with this please recycle it

- 1051** Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
 *J Sieper, J Braun, J Kay, S Badalamenti, A R Radin, L Jiao, S Fiore, T Momtahan, G D Yancopoulos, N Stahl, R D Inman*
- 1058** MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/Ia randomised, double-blind, placebo-controlled, dose-escalation trial
 *F Behrens, P P Tak, M Østergaard, R Støilov, P Wiland, T W Huizinga, V Y Berenfs, S Vladava, J Rech, A Rubbert-Roth, M Korkosz, D Rekalov, I A Zupanets, B J Eijlberg, J Geiseler, J Fresenius, R P Koroliewicz, A J Schottelius, H Burkhardt*
- 1065** Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy
H Yun, F Xie, E Delzell, L Chen, E B Levitan, J D Lewis, K G Saag, T Beukelman, K Winthrop, J W Baddley, J R Curtis
- 1072** Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study
 *T Bongartz, K N Glazebrook, S J Kavros, N S Murthy, S P Merry, W B Franz III, C J Michet, B M A Veetil, J M Davis III, T G Mason II, K J Warrington, S R Ytterberg, E L Matteson, C S Crowson, S Leng, C H McCollough*
- 1078** Comparison of *Tripterygium wilfordii* Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial
Q-w Lv, W Zhang, Q Shi, W-j Zheng, X Li, H Chen, Q-j Wu, W-I Jiang, H-b Li, L Gong, W Wei, H Liu, A-j Liu, H-t Jin, J-x Wang, X-m Liu, Z-b Li, B Liu, M Shen, Q Wang, X-n Wu, D Liang, Y-f Yin, Y-y Fei, J-m Su, L-d Zhao, Y Jiang, J Li, F-I Tang, F-c Zhang, P E Lipsky, X Zhang
- 1087** Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
 *L K Mercer, M Lunt, A L S Low, W G Dixon, K D Watson, D P M Symmons, K L Hyrich, BSRBR Control Centre Consortium*
- 1094** Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
 *J K Eriksson, J A Karlsson, J Bratt, I F Petersson, R F van Vollenhoven, S Ernestam, P Geborek, M Neovius*
- 1102** Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial
 *K Hambarzumyan, R Bolce, S Saevarsdottir, S E Cruickshank, E H Sasso, D Chernoff, K Forslund, I F Petersson, P Geborek, R F van Vollenhoven*
- 1110** Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
 *H I Brunner, N Ruperto, Z Zuber, C Keane, O Harari, A Kenwright, P Lu, R Cuttica, V Keltsev, R M Xavier, I Calvo, I Nikishina, N Rubio-Pérez, E Alexeeva, V Chasnylek, G Horneff, V Opoka-Winiarska, P Quartier, C A Silva, E Silverman, A Spindler, E Baildam, M L Gámir, A Martin, C Rietschel, D Siri, E Smolewska, D Lovell, A Martini, F De Benedetti, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)*
- 1118** Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis
I del Rincón, J F Polak, D H O'Leary, D F Battafarano, J M Erikson, J F Restrepo, E Molina, A Escalante
- 1124** Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database
B Maurer, N Graf, B A Michel, U Müller-Ladner, L Czirják, C P Denton, A Tyndall, C Metzger, V Lanius, D Khanna, O Distler, EUSTAR co-authors
- 1132** How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
R Fleischmann, D van der Heijde, A S Koenig, R Pedersen, A Szumski, L Marshall, E Bananis
- 1138** Pegylated interferon- α -2b reduces corticosteroid requirement in patients with Behçet's disease with upregulation of circulating regulatory T cells and reduction of Th17
S Lightman, S R J Taylor, C Bunce, H Longhurst, W Lynn, R Moos, M Stanford, O Tomkins-Netzer, D Yang, V L Calder, D O Haskard
- 1145** Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project
 *M A Stoffer, J S Smolen, A Woolf, A Ambrozic, F Bergha, A Boonen, A Bosworth, L Carmona, M Dougados, M de Wit, J Erwin, V Fialka-Moser, R Ionescu, A-M Keenan, E Loza, R H Moe, R Greiff, P Olejnik, I F Petersson, A-C Rat, B Rozman, B Strömbeck, L Tanner, T Uhlig, T P M V Vieland, T A Stamm, The eumusc.net WP 5 Expert Panel*
- 1150** Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry
A Kavanaugh, S J Lee, J R Curtis, J D Greenberg, J M Kremer, L Soto, C J Etzel, V Cox, K Yoshida, G W Reed, D H Solomon
- 1156** MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16
 *M Østergaard, L T H Jacobsson, C Schaufelberger, M S Hansen, J W J Bijlsma, A Dudek, M Rell-Bakalarska, F Staelens, R Haake, B Sundman-Engberg, H Bliddal*
- 1164** A randomised trial of a brace for patellofemoral osteoarthritis targeting knee pain and bone marrow lesions
M J Callaghan, M J Parkes, C E Hutchinson, A D Gait, L M Forsythe, E J Marjanovic, M Lunt, D T Felson
- 1171** Rituximab for IgG4-related disease: a prospective, open-label trial
M N Carruthers, M D Topazian, A Khosroshahi, T E Witzig, Z S Wallace, P A Hart, V Deshpande, T C Smyrle, S Chari, J H Stone
- 1178** Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
R B Jones, S Furuta, J W C Tervaert, T Hauser, R Luqmani, M D Morgan, C A Peh, C O Savage, M Segelmark, V Tesar, P van Paassen, M Walsh, K Westman, D RW Jayne, for the European Vasculitis Society (EUVAS)

- 1183** Differences and similarities in rheumatology specialty training programmes across European countries
F Sivera, S Ramiro, N Cikes, M Dougados, L Gossec, T K Kvien, I E Lundberg, P Mandl, A Moorthy, S Panchal, J A P da Silva, J W Bijlsma, on behalf of the Working Group on Training in Rheumatology across Europe
- 1188** Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
S Jordan, J H W Distler, B Maurer, D Huscher, J M van Laar, Y Allam, O Distler, on behalf of the EUSTAR Rituximab study group
- 1195** An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial
E M Vital, S Dass, M H Buch, A C Rawstron, P Emery
- 1202** Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain
T J Schmitzer, E F Ekman, E L H Spierings, H S Greenberg, M D Smith, M T Brown, C R West, K M Verburg
- 1212** Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
E V Arkema, J Jonsson, E Baecklund, J Bruchfeld, N Feltelius, J Askeling, on behalf of the ARTIS Study Group
- 1218** Reference intervals of spinal mobility measures in normal individuals: the mobility study
S Ramiro, A van Tubergen, C Stolk, D van der Heijde, P Royston, R Landewé
- 1225** Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI
H W van Steenbergen, J A B van Nies, T W J Huizinga, J L Bloem, M Reijnen, A H M van der Helm-van Mil
- 1233** Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial
M M ter Wee, D den Uyl, M Boers, P Kerstens, M Nurmohamed, D van Schaardenburg, A E Voskuyl, W F Lems
- 1241** Efficacy of TNF α blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis
J Callhoff, J Sieper, A Weiß, A Zink, J Listing
- 1257** Inducible chondrocyte-specific overexpression of BMP2 in young mice results in severe aggravation of osteophyte formation in experimental OA without altering cartilage damage
E N B Davidson, E L Vitters, M B Bennink, P L E M van Lent, A P M van Caam, A B Blom, W B van den Berg, F A J van de Loo, P M van der Kraan
- 1265** Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis
Q Zhou, S Haupt, J T Kreuzer, A Hammitzsch, F Proft, C Neumann, J Leipe, M Witt, H Schulze-Koops, A Skapenko
- 1275** Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis
W Gao, J McCormick, M Connolly, E Balogh, D J Veale, U Fearon
- 1284** IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis
I E Adamopoulos, E Suzuki, C-C Chao, D Gorman, S Adda, E Mavrikakis, K Zarbalis, R Geissler, A Asio, W M Blumenschein, T Mcclanahan, R De Waal Malefyt, M E Gershwin, E P Bowman
- 1293** Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood
T Wang, X Sun, J Zhao, J Zhang, H Zhu, C Li, N Gao, Y Jia, D Xu, F-P Huang, N Li, L Lu, Z-G Li
- 1302** Th17 cells play a critical role in the development of experimental Sjögren's syndrome
X Lin, K Rui, J Deng, J Tian, X Wang, S Wang, K-H Ko, Z Jiao, V S-F Chan, C S Lau, X Cao, L Lu
- 1311** The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

D L Boyle, K Soma, J Hodge, A Kavanaugh, D Mandel, P Mease, R Shurmur, A K Singhal, N Wei, S Rosengren, I Kaplan, S Krishnaswami, Z Luo, J Bradley, G S Firestein
- 1317** Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages
C Beyer, J Huang, J Beer, Y Zhang, K Palumbo-Zerr, P Zerr, A Distler, C Dees, C Maier, L Munoz, G Krönke, S Uderhardt, O Distler, S Jones, S Rose-John, T Oravecz, G Schett, J HW Distler

Basic and translational research

- 1249** Leri's pleonosteosis, a congenital rheumatic disease, results from microduplication at 8q22.1 encompassing *GDF6* and *SDC2* and provides insight into systemic sclerosis pathogenesis
S Banka, S A Cain, S Carim, S B Daly, J E Urquhart, G Erdem, J Harris, M Bottomley, D Donnai, B Kerr, H Kingston, A Superti-Furga, S Unger, H Ennis, J Worthington, A L Herrick, C L R Merry, W W Yue, C M Kielty, W G Newman